Newron Pharmaceuticals S.p.A. (0QOI.L)
LSE · CHF
CHF 8.73 (-3.96%) as of
Key statistics
- EPS (TTM)
- -0.85
- 52-week range
- 4.12 – 10.40
- Beta
- 0.85
- Revenue (TTM)
- 10.42M
- Profit margin
- -283.56%
- Volume
- 1.10k
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
- Headquarters
- Bresso, MI, Italy
- Employees
- 27
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.